LINKINVAX
LinKinVax operates as a clinical-stage biotechnology company. LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI).
LINKINVAX
Social Links:
Industry:
Biotechnology Medical
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.linkinvax.com
Status:
Active
Total Funding:
4.35 M EUR
Investors List
Giorgio Anania
Giorgio Anania investment in Seed Round - LinKinVax
Rémi Gaston- Dreyfus
Rémi Gaston- Dreyfus investment in Seed Round - LinKinVax
Alain Tingaud
Alain Tingaud investment in Seed Round - LinKinVax
André-Jacques Auberton-Hervé
André-Jacques Auberton-Hervé investment in Seed Round - LinKinVax
Jean-Paul Kress
Jean-Paul Kress investment in Seed Round - LinKinVax
Geoffrey Duyk
Geoffrey Duyk investment in Seed Round - LinKinVax
Official Site Inspections
http://www.linkinvax.com Semrush global rank: 5.27 M Semrush visits lastest month: 1.56 K
- Host name: webacc3.sd5.ghst.net
- IP address: 155.133.138.5
- Location: Poland
- Latitude: 52.2394
- Longitude: 21.0362
- Timezone: Europe/Warsaw
More informations about "LinKinVax"
LinKinVax - Crunchbase Company Profile & Funding
LinKinVax operates as a clinical-stage biotechnology company. LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by …See details»
LinKinVax - LinkedIn
LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. | We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a...See details»
LinKinVax Company Profile: Overview and Full News Analysis
LinKinVax is a French biotechnology startup located in Ile-de-France, leading the revolution in vaccine development. The company focuses on accelerating the process of creating highly …See details»
Results from a Phase I clinical trial of a dendritic cell targeting ...
Oct 2, 2024 · EnnoDC, the trading name of LinKinVax, is a clinical-stage biotech company pioneering the development of first-in-class Dendritic Cell (DC)-targeting immunotherapies.See details»
LinKinVax Appoints Dr. Jiong Ma as Independent Board Member
May 4, 2022 · LinKinVax, a clinical-stage biotechnology company specializing in the treatment of infectious diseases and certain forms of cancer, announces the appointment of Dr. Jiong Ma …See details»
Start-up LinKinVax and Gustave Roussy enter into a ... - Inserm
LinKinVax is developing CD40HVac, a therapeutic vaccine against HPV-associated malignancies, based on a novel technology that directly targets dendritic cells (DCs), which play a crucial role …See details»
LinKinVax on LinkedIn: White House launching $5 billion program …
LinKinVax welcomes the @Project Next Gen USA from the The White House to accelerate the development of next generation #coronavirus #vaccines that offer…See details»
LinKinVax Raises €7.3M in Funding - FinSMEs
Jan 10, 2023 · LinKinVax, a Paris, France-based clinical-stage biotechnology company, raised €7.3M in funding. The round was led by André-Jacques Auberton-Hervé and In-Q-Tel. The …See details»
LinKinVax and Gustave Roussy Announced First Patient Dosed in …
Sep 18, 2023 · LinKinVax develops CD40HVac, a therapeutic vaccine for HPV-associated malignancies, based on an innovative technology directly targeting dendritic cells (DC), which …See details»
LinkinVax Raises $4.35M in Seed Funding - FinSMEs
Feb 11, 2022 · Founded in 2020 and led by André-Jacques Auberton-Hervé, Honorary Chairman and founder of SOITEC, and Prof. Yves Levy, MD, PhD, immunologist, and Director of the …See details»
LINKINVAX Raises €4.350 Million in Funding - PharmiWeb.com
Feb 10, 2022 · TO ACCELERATE THE DEVELOPMENT OF ITS INNOVATIVE VACCINE PLATFORMPARIS--(BUSINESS WIRE)--LinKinVax, a clinical-stage biotechnology company …See details»
LinKinVax on LinkedIn: LinKinVax and Gustave Roussy announced …
A major milestone for LinKinVax and a promising addition to the existing therapeutic arsenal for a #cancer that affects a growing population in need for innovative and effective therapeutic ...See details»
LinkinVAX Completes First Batch Production of “PanCov”, Its Next ...
Jul 20, 2023 · PARIS & TOULOUSE, France-- (BUSINESS WIRE)--LinKinVax, a clinical-stage biotechnology company, announced the manufacture and bottling of a GMP batch of its next …See details»
A Huge Boost for Mucosal Covid Vax Development (Next …
Mar 29, 2024 · Development of these vaccines has just received a massive boost. A global consortium is being funded to develop and then run human challenge trials of intranasal or …See details»
LinKinVax partners with Gustave Roussy for HPV vaccine
Jan 20, 2023 · Biotechnology company LinKinVax has collaborated with European cancer centre Gustave Roussy for a Phase I/IIa clinical trial of a new therapeutic vaccine candidate, …See details»
LinKinVax et GTP Bioways préparent un candidat vaccin ... - Les …
Mar 15, 2022 · La biotech parisienne LinKinVax va faire fabriquer un lot clinique de son candidat vaccin de deuxième génération contre la Covid-19 chez GTP Bioways à Toulouse, pour créer …See details»
Mucosal Covid Vaccines Advancing, Plus a New Type of Vax in …
Apr 30, 2024 · AeroVax (Canada) – inhaled vaccine is advancing to phase 2: This is an adenovirus-based vaccine developed by McMaster University, using several components of …See details»
Anti CD40 HPV vaccine - EnnoDC - AdisInsight - Springer
Oct 8, 2024 · An anti-CD40 HPV vaccine is being developed by EnnoDC (formerly LinKinVax) for the treatment of human papillomavirus (HPV) infections. The vaccine, designed.See details»
LinKinVax on LinkedIn: #dendriticcells #vaccine #immunology …
We are thrilled to announce that LinKinVax completed a new round of financing, initiated in 2022, for a total of euros €7,3 M . A warm thank you to our…See details»
LinKinVax - Raised $12.7M Funding from 8 investors - Tracxn
LinKinVax has raised a total funding of $12.7M over 3 rounds from 8 investors. Investors include Bpifrance, In-Q-Tel and 6 others. Their latest funding round was of $7.77M on Jan 09, 2023 .See details»